FGFR3 gene alterations
Showing 1 - 25 of 8,706
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)
Not yet recruiting
- Locally Advanced Urothelial Carcinoma
- +3 more
- (no location specified)
Sep 15, 2022
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life
Active, not recruiting
- FGFR1 Gene Amplification
- +18 more
- Pemigatinib
- Quality-of-Life Assessment
-
Scottsdale, Arizona
- +5 more
Oct 18, 2022
Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)
Recruiting
- Urinary Bladder Neoplasms
- +2 more
-
New York, New York
- +2 more
Jan 31, 2023
Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)
Recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 15, 2022
Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)
Recruiting
- Solid Tumor
- +4 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 28, 2023
Urothelial Carcinoma Trial in Shanghai (AZD4547)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Cancer Hospital
Oct 20, 2021
Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)
Recruiting
- Gastrointestinal Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Dec 7, 2022
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)
Recruiting
- Advanced or Recurrent Solid Tumors
- FGFR Gene Alterations
-
Aoba-ku, Sendai, Miyagi, Japan
- +4 more
May 9, 2022
NSCLC Trial in Suzhou (Pemigatinib)
Recruiting
- Non-Small Cell Lung Cancer
-
Suzhou, ChinaThe First Affiliated Hospital of Soochow University
Jan 14, 2022
Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose
Completed
- Solid Tumor
- Derazantinib low dose range
- +3 more
-
Scottsdale, Arizona
- +11 more
Mar 7, 2022
Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Recruiting
- Bladder Cancer
- +12 more
-
Raleigh, North CarolinaxCures Virtual Site
Sep 20, 2021
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma Trial in Australia, United States (Drug ICP-192)
Recruiting
- Advanced Solid Tumors
- +2 more
- Drug ICP-192
-
Tucson, Arizona
- +8 more
Jan 28, 2022
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
-
Palo Alto, California
- +9 more
Aug 2, 2022
Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))
Terminated
- Solid Tumours
- Debio1347 (CH5183284)
-
Boston, Massachusetts
- +7 more
Sep 8, 2020
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,
Not yet recruiting
- Recurrent Glioblastoma, IDH-Wildtype
- +2 more
- Biospecimen Collection
- +2 more
- (no location specified)
May 13, 2023
Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage
Completed
- Metastatic Breast Cancer
- +2 more
- Control group
- Case group
- (no location specified)
Jun 16, 2022
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,
Recruiting
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
- +2 more
- Futibatinib and Binimetinib
-
Santa Monica, California
- +2 more
Jun 2, 2022
